Deals channel feed – Endpoints News

Deals channel feed

Takeda fleshes out CNS pact with peptide drugmaker, setting aside $3.5B in future milestones

4 years ago

Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio

4 years ago

Shelling out $5B+, PerkinElmer pays the big bucks for antibody and reagent player

4 years ago

Pfizer bets $1B cash on the original protein degraders as technology nears prime time

4 years ago

After chiming in antibody to Covid-19 fight, Junshi drops $30M to kick off mRNA joint venture in China

4 years ago

The pivot: Turnstone Biologics opens a new chapter with a switch to clinical development and a new venture round to pay for it

4 years ago

PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action

4 years ago

Flexing its newfound wealth, BioNTech snaps up a TCR platform and manufacturing site as Gilead exits

4 years ago

Celularity emerges from SPAC merger doubled down on cell therapies as Bob Hariri downgrades ill-fated Covid-19 program

4 years ago

Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease

4 years ago

UK business secretary looking into Philip Morris' proposed deal to acquire Vectura — report

4 years ago

EU set to launch full-scale investigation into Grail-Illumina deal amid antitrust concerns — report

4 years ago

AstraZeneca's planned takeover of Alexion clears last regulatory review, deal to close next week

4 years ago

Eli Lilly swoops in to buy a small protein drug developer and its glucose responsive insulin in $1B-plus deal

4 years ago

Scoop: Activists' attempt to take over infamous Martin Shkreli company fails, as ‘Pharma Bro’ votes from prison

4 years ago

Struggling Ionis licenses Bicycle Therapeutics' platform in a bid to develop drugs that can cross blood-brain barrier

4 years ago

In search of a post-Tecfidera hit for MS, Biogen follows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of China

4 years ago

After monthslong lull, Big Pharma should be ready to pounce on M&A as market settles — analysts

4 years ago

Branching out from diabetes? Novo Nordisk shells out the big bucks for Prothena's ATTR amyloidosis pipeline

4 years ago

Kicking the habit, Philip Morris forges $1.5B deal to acquire Vectura in race to build a top inhaled-drug company

4 years ago

AstraZeneca takes a chance on the STING pathway with F-star

4 years ago

J&J, Sid Mukherjee's Vor team up to pair bispecifics with engineered stem cells for blood cancer

4 years ago

Eli Lilly makes modest bet on 'all-in-human' discovery outfit for ALS drugs, deepening bid in precision neurology

4 years ago

A faded penny stock player folds its cards and hands over the keys in reverse merger

4 years ago

First page Previous page 72 73 747576 77 78 Next page Last page